CONKO-011研究表明,与低分子量肝素相比,拜瑞妥®抗凝效果更优,肿瘤合并静脉血栓栓塞患者治疗满意度更高

2021-07-21 medsci medsci

本次结果是对 COSIMO 研究的补充,COSIMO研究表明从低分子量肝素切换到拜瑞妥®后患者满意度提高。

日前,在 2021 年 7 月 17 日至 21 日举行的第 29 届国际血栓与止血学会(ISTH)年会上,公布了一项前瞻性、随机、开放标签、III 期CONKO-011临床研究数据,结果显示:与低分子肝素治疗相比,拜瑞妥®(利伐沙班)治疗能够提高癌症相关静脉血栓栓塞患者的治疗满意度。

患者对抗凝治疗的满意度对于选择抗凝治疗的依从性至关重要。CONKO-011研究使用抗凝治疗量表(ACTS)测量了 247 名患者对抗凝治疗的满意度,这些患者被随机分配到拜瑞妥®组(n=123)或低分子量肝素组(n=124)。拜瑞妥®组患者在前三周内服用 15 mg BID,然后是 20 mg OD,低分子量肝素组的患者按照特定的治疗剂量指南给药。

研究发现使用拜瑞妥®治疗的患者报告满意度改善,特别是在减少抗凝治疗相关负担方面。 4、8 和 12 周后平均抗凝治疗量表负担结果拜瑞妥®组更好。这种负担减轻可能是减少患者提出终止治疗的一个因素(两组要求比例分别为拜瑞妥®组 11.1% 和低分子量肝素组 19.4%)。

静脉血栓栓塞和大出血事件在组间没有差异(复发性静脉血栓栓塞:低分子量肝素组5 例,拜瑞妥®组3 例;大出血:拜瑞妥®组5 例;低分子量肝素5 例)。

CONKO-011研究是 CALLISTO 研究项目的一部分,该项目考察拜瑞妥®在各种癌症类型,各种患者状况中的使用,在评估传统安全性和有效性结果的同时,还评估患者偏好、治疗满意度和生活质量。本次结果是对 COSIMO 研究的补充,COSIMO研究表明从低分子量肝素切换到拜瑞妥®后患者满意度提高。另外,SELECT-D研究结果表明:与低分子量肝素相比,使用拜瑞妥®治疗的患者静脉血栓栓塞复发减少,而大出血事件发生两者相当。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1955543, encodeId=f1881955543c1, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Thu Oct 14 11:33:38 CST 2021, time=2021-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1698237, encodeId=a81e169823ee7, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Fri Apr 01 06:33:38 CST 2022, time=2022-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1744143, encodeId=4c231e4414373, content=<a href='/topic/show?id=8a5d56256fb' target=_blank style='color:#2F92EE;'>#拜瑞妥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56256, encryptionId=8a5d56256fb, topicName=拜瑞妥)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Mon Aug 16 06:33:38 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984808, encodeId=ef2b19848084b, content=<a href='/topic/show?id=48c426158a7' target=_blank style='color:#2F92EE;'>#低分子量肝素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26158, encryptionId=48c426158a7, topicName=低分子量肝素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cb02500048, createdName=ms6832696159214430, createdTime=Thu Sep 09 06:33:38 CST 2021, time=2021-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379594, encodeId=d80613e9594b7, content=<a href='/topic/show?id=31765625e52' target=_blank style='color:#2F92EE;'>#拜瑞妥®#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56257, encryptionId=31765625e52, topicName=拜瑞妥®)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Jun 12 00:33:38 CST 2021, time=2021-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478708, encodeId=f46a14e8708f0, content=<a href='/topic/show?id=d561665e7af' target=_blank style='color:#2F92EE;'>#满意度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66577, encryptionId=d561665e7af, topicName=满意度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1627448984, createdName=ms1692212821629096, createdTime=Sat Jun 12 00:33:38 CST 2021, time=2021-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047363, encodeId=6774104e36387, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Thu Jun 10 12:33:38 CST 2021, time=2021-06-10, status=1, ipAttribution=)]
    2021-10-14 xue8602
  2. [GetPortalCommentsPageByObjectIdResponse(id=1955543, encodeId=f1881955543c1, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Thu Oct 14 11:33:38 CST 2021, time=2021-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1698237, encodeId=a81e169823ee7, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Fri Apr 01 06:33:38 CST 2022, time=2022-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1744143, encodeId=4c231e4414373, content=<a href='/topic/show?id=8a5d56256fb' target=_blank style='color:#2F92EE;'>#拜瑞妥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56256, encryptionId=8a5d56256fb, topicName=拜瑞妥)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Mon Aug 16 06:33:38 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984808, encodeId=ef2b19848084b, content=<a href='/topic/show?id=48c426158a7' target=_blank style='color:#2F92EE;'>#低分子量肝素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26158, encryptionId=48c426158a7, topicName=低分子量肝素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cb02500048, createdName=ms6832696159214430, createdTime=Thu Sep 09 06:33:38 CST 2021, time=2021-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379594, encodeId=d80613e9594b7, content=<a href='/topic/show?id=31765625e52' target=_blank style='color:#2F92EE;'>#拜瑞妥®#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56257, encryptionId=31765625e52, topicName=拜瑞妥®)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Jun 12 00:33:38 CST 2021, time=2021-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478708, encodeId=f46a14e8708f0, content=<a href='/topic/show?id=d561665e7af' target=_blank style='color:#2F92EE;'>#满意度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66577, encryptionId=d561665e7af, topicName=满意度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1627448984, createdName=ms1692212821629096, createdTime=Sat Jun 12 00:33:38 CST 2021, time=2021-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047363, encodeId=6774104e36387, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Thu Jun 10 12:33:38 CST 2021, time=2021-06-10, status=1, ipAttribution=)]
    2022-04-01 fusion
  3. [GetPortalCommentsPageByObjectIdResponse(id=1955543, encodeId=f1881955543c1, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Thu Oct 14 11:33:38 CST 2021, time=2021-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1698237, encodeId=a81e169823ee7, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Fri Apr 01 06:33:38 CST 2022, time=2022-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1744143, encodeId=4c231e4414373, content=<a href='/topic/show?id=8a5d56256fb' target=_blank style='color:#2F92EE;'>#拜瑞妥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56256, encryptionId=8a5d56256fb, topicName=拜瑞妥)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Mon Aug 16 06:33:38 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984808, encodeId=ef2b19848084b, content=<a href='/topic/show?id=48c426158a7' target=_blank style='color:#2F92EE;'>#低分子量肝素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26158, encryptionId=48c426158a7, topicName=低分子量肝素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cb02500048, createdName=ms6832696159214430, createdTime=Thu Sep 09 06:33:38 CST 2021, time=2021-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379594, encodeId=d80613e9594b7, content=<a href='/topic/show?id=31765625e52' target=_blank style='color:#2F92EE;'>#拜瑞妥®#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56257, encryptionId=31765625e52, topicName=拜瑞妥®)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Jun 12 00:33:38 CST 2021, time=2021-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478708, encodeId=f46a14e8708f0, content=<a href='/topic/show?id=d561665e7af' target=_blank style='color:#2F92EE;'>#满意度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66577, encryptionId=d561665e7af, topicName=满意度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1627448984, createdName=ms1692212821629096, createdTime=Sat Jun 12 00:33:38 CST 2021, time=2021-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047363, encodeId=6774104e36387, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Thu Jun 10 12:33:38 CST 2021, time=2021-06-10, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1955543, encodeId=f1881955543c1, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Thu Oct 14 11:33:38 CST 2021, time=2021-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1698237, encodeId=a81e169823ee7, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Fri Apr 01 06:33:38 CST 2022, time=2022-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1744143, encodeId=4c231e4414373, content=<a href='/topic/show?id=8a5d56256fb' target=_blank style='color:#2F92EE;'>#拜瑞妥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56256, encryptionId=8a5d56256fb, topicName=拜瑞妥)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Mon Aug 16 06:33:38 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984808, encodeId=ef2b19848084b, content=<a href='/topic/show?id=48c426158a7' target=_blank style='color:#2F92EE;'>#低分子量肝素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26158, encryptionId=48c426158a7, topicName=低分子量肝素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cb02500048, createdName=ms6832696159214430, createdTime=Thu Sep 09 06:33:38 CST 2021, time=2021-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379594, encodeId=d80613e9594b7, content=<a href='/topic/show?id=31765625e52' target=_blank style='color:#2F92EE;'>#拜瑞妥®#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56257, encryptionId=31765625e52, topicName=拜瑞妥®)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Jun 12 00:33:38 CST 2021, time=2021-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478708, encodeId=f46a14e8708f0, content=<a href='/topic/show?id=d561665e7af' target=_blank style='color:#2F92EE;'>#满意度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66577, encryptionId=d561665e7af, topicName=满意度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1627448984, createdName=ms1692212821629096, createdTime=Sat Jun 12 00:33:38 CST 2021, time=2021-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047363, encodeId=6774104e36387, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Thu Jun 10 12:33:38 CST 2021, time=2021-06-10, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1955543, encodeId=f1881955543c1, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Thu Oct 14 11:33:38 CST 2021, time=2021-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1698237, encodeId=a81e169823ee7, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Fri Apr 01 06:33:38 CST 2022, time=2022-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1744143, encodeId=4c231e4414373, content=<a href='/topic/show?id=8a5d56256fb' target=_blank style='color:#2F92EE;'>#拜瑞妥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56256, encryptionId=8a5d56256fb, topicName=拜瑞妥)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Mon Aug 16 06:33:38 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984808, encodeId=ef2b19848084b, content=<a href='/topic/show?id=48c426158a7' target=_blank style='color:#2F92EE;'>#低分子量肝素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26158, encryptionId=48c426158a7, topicName=低分子量肝素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cb02500048, createdName=ms6832696159214430, createdTime=Thu Sep 09 06:33:38 CST 2021, time=2021-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379594, encodeId=d80613e9594b7, content=<a href='/topic/show?id=31765625e52' target=_blank style='color:#2F92EE;'>#拜瑞妥®#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56257, encryptionId=31765625e52, topicName=拜瑞妥®)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Jun 12 00:33:38 CST 2021, time=2021-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478708, encodeId=f46a14e8708f0, content=<a href='/topic/show?id=d561665e7af' target=_blank style='color:#2F92EE;'>#满意度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66577, encryptionId=d561665e7af, topicName=满意度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1627448984, createdName=ms1692212821629096, createdTime=Sat Jun 12 00:33:38 CST 2021, time=2021-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047363, encodeId=6774104e36387, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Thu Jun 10 12:33:38 CST 2021, time=2021-06-10, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1955543, encodeId=f1881955543c1, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Thu Oct 14 11:33:38 CST 2021, time=2021-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1698237, encodeId=a81e169823ee7, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Fri Apr 01 06:33:38 CST 2022, time=2022-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1744143, encodeId=4c231e4414373, content=<a href='/topic/show?id=8a5d56256fb' target=_blank style='color:#2F92EE;'>#拜瑞妥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56256, encryptionId=8a5d56256fb, topicName=拜瑞妥)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Mon Aug 16 06:33:38 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984808, encodeId=ef2b19848084b, content=<a href='/topic/show?id=48c426158a7' target=_blank style='color:#2F92EE;'>#低分子量肝素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26158, encryptionId=48c426158a7, topicName=低分子量肝素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cb02500048, createdName=ms6832696159214430, createdTime=Thu Sep 09 06:33:38 CST 2021, time=2021-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379594, encodeId=d80613e9594b7, content=<a href='/topic/show?id=31765625e52' target=_blank style='color:#2F92EE;'>#拜瑞妥®#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56257, encryptionId=31765625e52, topicName=拜瑞妥®)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Jun 12 00:33:38 CST 2021, time=2021-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478708, encodeId=f46a14e8708f0, content=<a href='/topic/show?id=d561665e7af' target=_blank style='color:#2F92EE;'>#满意度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66577, encryptionId=d561665e7af, topicName=满意度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1627448984, createdName=ms1692212821629096, createdTime=Sat Jun 12 00:33:38 CST 2021, time=2021-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047363, encodeId=6774104e36387, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Thu Jun 10 12:33:38 CST 2021, time=2021-06-10, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1955543, encodeId=f1881955543c1, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Thu Oct 14 11:33:38 CST 2021, time=2021-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1698237, encodeId=a81e169823ee7, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Fri Apr 01 06:33:38 CST 2022, time=2022-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1744143, encodeId=4c231e4414373, content=<a href='/topic/show?id=8a5d56256fb' target=_blank style='color:#2F92EE;'>#拜瑞妥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56256, encryptionId=8a5d56256fb, topicName=拜瑞妥)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Mon Aug 16 06:33:38 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984808, encodeId=ef2b19848084b, content=<a href='/topic/show?id=48c426158a7' target=_blank style='color:#2F92EE;'>#低分子量肝素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26158, encryptionId=48c426158a7, topicName=低分子量肝素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cb02500048, createdName=ms6832696159214430, createdTime=Thu Sep 09 06:33:38 CST 2021, time=2021-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379594, encodeId=d80613e9594b7, content=<a href='/topic/show?id=31765625e52' target=_blank style='color:#2F92EE;'>#拜瑞妥®#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56257, encryptionId=31765625e52, topicName=拜瑞妥®)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Jun 12 00:33:38 CST 2021, time=2021-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478708, encodeId=f46a14e8708f0, content=<a href='/topic/show?id=d561665e7af' target=_blank style='color:#2F92EE;'>#满意度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66577, encryptionId=d561665e7af, topicName=满意度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1627448984, createdName=ms1692212821629096, createdTime=Sat Jun 12 00:33:38 CST 2021, time=2021-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047363, encodeId=6774104e36387, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Thu Jun 10 12:33:38 CST 2021, time=2021-06-10, status=1, ipAttribution=)]
    2021-06-10 CHANGE

    疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的

    0

相关资讯

JAMA:局部枸橼酸盐vs全身肝素抗凝对持续肾脏替代治疗过滤器寿命及患者死亡率的影响

在接受持续肾脏替代治疗的急性肾损伤危重患者中,与全身肝素抗凝相比,局部枸橼酸盐抗凝可显著延长过滤器寿命,但抗凝治疗对患者死亡率的影响差异不显著

Am J Hematology: 新冠患者接受抗凝治疗可以减少死亡率

血栓形成是COVID-19病毒造成的新冠肺炎患者中最具破坏性的并发症之一。在多项研究中,已经报道了静脉血栓栓塞症(VTE)。

AJG: 抗凝药物与经颈静脉肝内门静脉分流术治疗肝硬化门静脉血栓的疗效差异分析

门静脉血栓形成(PVT)在肝硬化过程中并不罕见,它发生的风险会随着肝病严重程度的增加而增加。 阻塞性和广泛的PVT无疑与肝病相关的死亡率明显相关。

JACC:生物瓣膜血栓形成患者远期的抗凝预后研究

在生物瓣膜血栓形成(BPVT)的早期预防和治疗中,抗凝是有效的,但BPVT后的长期疗效尚不清楚。本研究的目的旨在评估接受抗凝治疗的BPVT患者的远期预后。本研究纳入分析了83名因疑似BPVT接受华法林治疗的患者(平均年龄57±18岁,男性占54%),并与166名匹配对照进行对比分析。有62名患者在抗凝治疗后的3个月内心超结果转为正常,21名患者对华法林无反应。经过平均34个月时间的随访,病例组和对

JAHA:抗凝房颤患者出血后新发癌症诊断分析

在接受口服抗凝治疗的AF患者中,任何胃肠道、泌尿生殖道或支气管肺部出血与新发癌症的诊断率升高有关。这些出血事件应促使对这些部位的癌症进行筛查。

Annals of Neurology :房颤提前口服抗凝,有助于降低脑中风严重性,改善溶栓预后

房颤提前口服抗凝,有助于降低脑中风严重性,改善溶栓预后